Results from Pfizer/BioNTech's Covid-19 clinical trial in 12 to 15 year olds mean that age group in the US could receive vaccines as soon as the fall, Dr. Peter Hotez, co-director of the Center for Vaccine Development at Texas Children's Hospital, told CNN.
The vaccine was 100% effective in preventing symptomatic Covid-19, the companies said, and was well tolerated.
“I think it’s likely a green light to move forward, to move down in terms of vaccinating adolescents 12 to 15,” Hotez said.
He added that "by the fall I think there’s a good possibility we’ll be vaccinating teenagers, 12 and up."
"And for middle schools, junior high schools, high schools, it’s really good news in the United States for both teachers and staff. We’ll have teachers and staff vaccinated, we’ll have the students vaccinated in those middle schools and high schools.”
Pfizer/BioNTech plan to submit the data to the US Food and Drug Administration as soon as possible for expanded emergency use authorization of the two-dose vaccine.
The trial included 2,260 participants, and while Hotez said this was a relatively small study, he said he thought it was enough to move ahead with.